NCT03542006

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Tel-Aviv Sourasky Medical Center · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Detailed description

Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. However, this treatment carries the risk of severe side effects. The goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DRUG	Brinzolamide Ophthalmic	Topical brinzolamide given bd for 3 months

Timeline

• Start date: 2018-06-01
• Primary completion: 2019-01-01
• Completion: 2019-04-01
• First posted: 2018-05-31
• Last updated: 2018-05-31

Locations

2 sites across 2 countries: Argentina, Israel